ARCHIVES

Retraction Based On Data Given To Duke Last November, But Apparently Disregarded

This article is from The Cancer Letter archive.

Vol. 36 No. 39 | October 29, 2010

Download PDF Visit The Full Archive

Related Articles

FDA Committee Agenda Includes M-AMSA, THC, Estramustine, Platinum

May 22, 1981

Senate Committee Investigating Pharma’s “Educational Grants.”

January 20, 2006

In Brief: Jay Moskowitz Reassigned; Healy To Run For Ohio Republican Nomination To Senate

September 17, 1993

NCI Plans Trials of Burzynski’s ‘Antineoplaston’; JAMA Report Says No Antitumor Activity In Tests

June 5, 1992

RFA On Hepatitis B Virus, Liver Cancer

April 15, 1983

Surgical Oncologists Certification Asked By SSO Workshop

December 9, 1983